Status:

COMPLETED

Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer

Lead Sponsor:

Eric Winer, MD

Collaborating Sponsors:

Dana-Farber Cancer Institute

Brigham and Women's Hospital

Conditions:

Breast Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to find out what effects the preoperative combination therapies of herceptin/navelbine or herceptin/taxotere/carboplatin will have on patients with early stage HER-2 posit...

Detailed Description

Before starting treatment, a clip will be placed via catheter into the tumor bed, so the surgeon can locate the site of the tumor. During clip placement, tissue biopsy will be taken of the tumor. One ...

Eligibility Criteria

Inclusion

  • Patients with stage II or III breast cancer
  • HER-2 positive tumors
  • Older than 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of greater or equal to 1.
  • ANC \> 1,500/mm3
  • Hemoglobin \> 9gm/dl
  • Platelets \> 100,000mm3
  • Creatinine \< 2mg/dl
  • Glucose \< 200mg/dl
  • Bilirubin \< 1.5 x ULN

Exclusion

  • Previous treatment with herceptin, taxanes, doxorubicin or other anthracycline-type therapy, navelbine, or platinum-based therapy.
  • Pregnant or breast-feeding women
  • Serious illness, or medical or psychiatric condition
  • Uncontrolled infections
  • Active or severe cardiovascular or pulmonary disease
  • Patients with left ventricular ejection fraction \< 50%
  • Peripheral neuropathy of any etiology that exceeds grade 1
  • Prior history of malignancy
  • Uncontrolled diabetes

Key Trial Info

Start Date :

December 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2011

Estimated Enrollment :

81 Patients enrolled

Trial Details

Trial ID

NCT00148668

Start Date

December 1 2003

End Date

August 1 2011

Last Update

April 9 2013

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Yale Cancer Center

New Haven, Connecticut, United States, 06520

2

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02115

3

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115

4

Massachusetts General Hospital

Boston, Massachusetts, United States, 02115

Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer | DecenTrialz